Functional genomics · Perturbation biology · Broad Institute
Leading large-scale perturbation screening from assay signal to experimental follow-up.
I lead computational development for PROSPECT, analyzing 100K+ small-molecule compounds from barcode and replicate QC through dose-response modeling, hit prioritization, and mechanism-of-action inference. I partner with experimental scientists to define analytical requirements and go/no-go criteria, diagnose assay issues, and guide follow-up experiments. Reusable Nextflow workflows support the analytical process.
- Scale
- 100K+ compounds
- Ownership
- Computational lead
- Outcome
- Top 1% prioritized
Screening methods and context →
Virtual screening · MoA inference · Candidate prioritization · Compound triage
Turning virtual-screening predictions into biologically informed compound-selection decisions.
I built the analytical pipeline for mechanism-of-action inference and candidate prioritization, guide selection-algorithm design, and evaluate strategies for scaffold generalization and biological relevance. Deterministic medicinal-chemistry and ADMET triage connects DuckDB-backed results with Streamlit scientist review.
- Scale
- 10B+ compounds
- Analysis
- MoA + scaffold-aware prioritization
- Decision
- Human-reviewed compound triage
See methods and final triage →